Fampridine (Fampyra®)

Assessment Status Assessment process complete
Drug Fampridine
Brand Fampyra®
Indication For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
Assessment Process
Rapid review commissioned 01/09/2011
Rapid review completed 26/09/2011
Rapid review outcome Full Pharmaconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 23/05/2012
NCPE assessment completed 17/08/2012
NCPE assessment outcome Reimbursement not recommended

As the manufacturer is unable to demonstrate the cost-effectiveness of fampridine we are unable to recommend reimbursement


Technical Summary